VLRX - Valeritas Holdings, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
2.1400
-0.0900 (-4.04%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close2.2300
Open2.2000
Bid2.1200 x 4000
Ask2.2200 x 1000
Day's Range2.1000 - 2.2200
52 Week Range2.1000 - 33.2000
Volume82,066
Avg. Volume584,006
Market Cap15.317M
Beta (3Y Monthly)1.84
PE Ratio (TTM)N/A
EPS (TTM)-14.5540
Earnings DateAug 8, 2017 - Aug 14, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est13.00
Trade prices are not sourced from all markets
  • GlobeNewswire

    Clinical Trial Evaluating Delivery of Regular Human Insulin vs. Rapid Acting Insulin Delivered by Valeritas’ V-Go® Meets Primary A1c Endpoint

    Valeritas Holdings, Inc. (VLRX), a medical technology company and maker of V-Go® Wearable Insulin Delivery device, a simple, all-in-one, wearable insulin delivery option for patients with diabetes, today announced that a randomized controlled trial comparing the delivery of U-100 Regular Human Insulin (RHI) by V-Go versus delivery of Rapid Acting Insulin (RAI) by V-Go in patients with type 2 diabetes has met the primary A1c (blood sugar levels) endpoint.

  • Thomson Reuters StreetEvents

    Edited Transcript of VLRX earnings conference call or presentation 8-Aug-19 8:30pm GMT

    Q2 2019 Valeritas Holdings Inc Earnings Call

  • Valeritas Holdings, Inc. (VLRX) Reports Q2 Loss, Tops Revenue Estimates
    Zacks

    Valeritas Holdings, Inc. (VLRX) Reports Q2 Loss, Tops Revenue Estimates

    Valeritas Holdings, Inc. (VLRX) delivered earnings and revenue surprises of 5.86% and 0.19%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    Valeritas Announces Second Quarter 2019 Financial Results

    BRIDGEWATER, N.J., Aug. 08, 2019 -- Valeritas Holdings, Inc. (NASDAQ: VLRX), a medical technology company and maker of V-Go® Wearable Insulin Delivery device, a simple,.

  • Benzinga

    A Look At Benzinga Pro's Most-Searched Tickers For August 5, 2019

    This most-searched list is a feature included in Benzinga Pro's Newsfeed tool. It highlights stocks frequently searched by Benzinga Pro users on the platform. Allakos (NASDAQ: ALLK ) shares were up 112.6% ...

  • GlobeNewswire

    Preclinical Study Shows Valeritas Proprietary h-Patch™ Wearable Delivery Device an Effective Option for Continuous Infusion of Apomorphine

    Valeritas Holdings, Inc. (VLRX), a medical technology company and maker of the V-Go® Wearable Insulin Delivery device, which uses its proprietary h-Patch™ technology, announced today positive results from a preclinical pharmacokinetic (PK) study of apomorphine (Apo) subcutaneous infusion delivered via its h-Patch™ wearable drug delivery device. Valeritas’ h-Patch™ is a drug delivery technology that can facilitate the simple and effective subcutaneous delivery of injectable medicines to patients across a broad range of therapeutic areas.

  • Will Valeritas Holdings, Inc. (VLRX) Report Negative Earnings Next Week? What You Should Know
    Zacks

    Will Valeritas Holdings, Inc. (VLRX) Report Negative Earnings Next Week? What You Should Know

    Valeritas Holdings, Inc. (VLRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Benzinga

    Valeritas Rallies On Positive Preclinical Data For CBD Delivery Using Wearable Device

    Valeritas Holdings Inc (NASDAQ: VLRX) shares have shed more than 61% in the year-to-date period. Valeritas, which makes the V-Go – Wearable Insulin Delivery Device using its proprietary h-Patch technology, announced positive results from a preclinical pharmacokinetic study of cannabidiol subcutaneous infusion with two dosing regimens delivered using its proprietary h-Patch wearable drug delivery device. The pharmacokinetics evaluated at time points up to 48 hours from the start of infusion showed that both dosages displayed rapid absorption and distribution with CBD levels in blood detected within an hour of the start of the infusion, Valeritas said.

  • GlobeNewswire

    Cannabidiol (CBD) Effectively Delivered Subcutaneously with Valeritas Proprietary h-Patch™ Wearable Device in Preclinical Study

    Valeritas Holdings, Inc. (VLRX), a medical technology company and maker of the V-Go® Wearable Insulin Delivery device, which uses their proprietary h-Patch™ technology, announced today positive results from a preclinical pharmacokinetic (PK) study of cannabidiol (CBD) subcutaneous infusion with two dosing regimens delivered via its proprietary h-Patch™ wearable drug delivery device. The Company believes this study represents the first report of CBD delivered via subcutaneous infusion in any preclinical model.

  • Zacks.com featured highlights include: Amedisys, AbbVie, Laureate, Genesco and Valeritas
    Zacks

    Zacks.com featured highlights include: Amedisys, AbbVie, Laureate, Genesco and Valeritas

    Zacks.com featured highlights include: Amedisys, AbbVie, Laureate, Genesco and Valeritas

  • Use Rising P/E Strategy to Buy 5 Winning Stocks
    Zacks

    Use Rising P/E Strategy to Buy 5 Winning Stocks

    Cross the age-old barrier of low P/E investing, bet on these five stocks that boast rising P/E.

  • GlobeNewswire

    Valeritas to Report Second Quarter 2019 Financial Results on August 8, 2019

    Valeritas Holdings, Inc. (VLRX), a medical technology company and maker of V-Go® Wearable Insulin Delivery device, a simple, all-in-one, wearable insulin delivery option for patients with diabetes, today announced that it will release financial results for the second quarter of 2019 after the close of trading on Thursday, August 8, 2019. Valeritas’ management team will host a corresponding conference call beginning at 4:30 p.m. ET. Valeritas is a commercial-stage medical technology company focused on improving health and simplifying life for people with diabetes by developing and commercializing innovative technologies.

  • Benzinga

    A Look At Benzinga Pro's Most-Searched Tickers For July 11, 2019

    This most-searched list is a feature included in Benzinga Pro's Newsfeed tool. It highlights stocks frequently searched by Benzinga Pro users on the platform. Vislink Technologies, Inc. (NASDAQ: VISL ) ...

  • GlobeNewswire

    Valeritas’ V-Go® Wearable Insulin Delivery Device Demonstrates Economic Advantages Compared to Multiple Daily Injection Therapy for Insulin Dependent Type 2 Diabetes Population

    BRIDGEWATER, N.J., July 08, 2019 -- Valeritas Holdings, Inc. (NASDAQ: VLRX), a medical technology company and maker of the V-Go® Wearable Insulin Delivery device, announced.

  • GlobeNewswire

    Valeritas Files Special 510(k) with FDA for Labeling Change to Include the Use of Regular Human Insulin In V-Go® Wearable Insulin Delivery Device

    Valeritas Holdings, Inc. (VLRX), a medical technology company and maker of V-Go® Wearable Insulin Delivery device, today announced it has filed a “Special 510(k): Device Modification” submission with the FDA  that includes using regular human insulin (RHI) in the device. A small peer-reviewed study published in Clinical Diabetes in October 2016 concluded that use of RHI administered by V-Go resulted in improved glycemic control with an estimated annual direct pharmacy costs savings exceeding $3,000 (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5070587/). “Valeritas is focused on solutions that are both highly effective and help patients reduce their costs in managing diabetes.

  • GlobeNewswire

    Valeritas Announces Milestone of 20 Million V-Go® Insulin Delivery Devices Sold

    Valeritas Holdings, Inc. (VLRX), a medical technology company and maker of the V-Go® Wearable Insulin Delivery device, announced today it has surpassed a significant milestone of selling more than 20 million V-Go insulin delivery devices in the United States. “There are millions of patients with type 2 diabetes on insulin therapy in the United States, and the majority are not meeting their A1c or blood sugar goal,” said John Timberlake, President and Chief Executive Officer of Valeritas. Valeritas is a commercial-stage medical technology company focused on improving health and simplifying life for people with diabetes by developing and commercializing innovative technologies.

  • Thomson Reuters StreetEvents

    Edited Transcript of VLRX earnings conference call or presentation 9-May-19 8:30pm GMT

    Q1 2019 Valeritas Holdings Inc Earnings Call

  • GlobeNewswire

    Valeritas’ V-Go® Wearable Insulin Delivery Device Demonstrates a Reduction in A1c Levels by 1.3 when Intensifying from a Basal Insulin Regimen to Basal-Bolus Delivery

    Valeritas Holdings, Inc. (VLRX), a medical technology company and maker of V-Go® Wearable Insulin Delivery device, today announced additional positive data from the VERDICT study was presented at the American Diabetes Association's 79th Scientific Sessions held in San Francisco, California. “Insulin therapy is often intensified utilizing a stepwise approach of adding one injection at a time due to the increased burden and complexity associated with basal-bolus therapy,” said Trisha Zeidan, MD, Principal Investigator of the VERDICT Study and affiliated with Premier Physician Network, Bull Family Diabetes Center.

  • GlobeNewswire

    Valeritas Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    Valeritas Holdings, Inc. (VLRX), a medical technology company and maker of V-Go® Wearable Insulin Delivery device, today announced that the Compensation Committee of Valeritas’ Board of Directors granted stock options to purchase an aggregate of 6,430 shares of Valeritas’ common stock to 6 newly-hired employees, with a grant date of May 29, 2019, pursuant to the Valeritas Holdings, Inc. 2018 Inducement Plan that was previously disclosed. The stock options were granted as inducements material to the new employees entering into employment with Valeritas in accordance with NASDAQ Listing Rule 5635(c)(4).

  • GlobeNewswire

    Valeritas to Participate in the American Diabetes Association’s 79th Scientific Sessions; Company Reiterates Second Quarter and Full-Year 2019 Revenue Guidance

    Valeritas Holdings, Inc. (VLRX), a medical technology company and maker of V-Go® Wearable Insulin Delivery device, announced today it will participate in this year’s American Diabetes Association’s (ADA) 79th Scientific Sessions at the Moscone Center in San Francisco, CA, on June 7-11, 2019. Additionally, Valeritas reiterated its second quarter 2019 revenue guidance of $7.4 million to $7.6 million and its 2019 annual revenue guidance of $31.0 million to $34.0 million. Also, the Company now expects to end the second quarter with $27 million in cash and cash equivalents vs. the original estimate of $25 million with the Company’s current cash position now allowing it to operate into February 2020, assuming no additional capital or non-dilutive financing.

  • GlobeNewswire

    American Diabetes Association Includes “Disposable Patch-Like Device,” such as V-Go® from Valeritas, in the ADA Standards of Medical Care in Diabetes - 2019

    Valeritas Holdings, Inc. (VLRX), a medical technology company and maker of V-Go® Wearable Insulin Delivery device, today announced the inclusion by the American Diabetes Association (ADA) of the use of a “disposable patch-like device” for insulin delivery in the new Diabetes Technology chapter of ADA’s annual Standards of Medical Care in Diabetes for 2019, published in Diabetes Care. The inclusion in this year’s Standards of Care marks the first time such a device has been incorporated in ADA’s current clinical practice recommendations.

  • GlobeNewswire

    Valeritas’ V-Go® Demonstrates Positive Impact in Diabetes Quality Performance Measures in an Older Adult Population

    Valeritas Holdings, Inc. (VLRX), a medical technology company and maker of V-Go® Wearable Insulin Delivery device, today announced additional data from the VERDICT study at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Annual Meeting. “The VERDICT study demonstrates that significantly more patients achieved better control and attained improved quality metrics.  We will continue to partner with clinicians to improve patient outcomes and quality of care delivered using V-Go as a standard way to deliver basal-bolus insulin therapy,” said John Timberlake, President and Chief Executive Officer of Valeritas. Valeritas is a commercial-stage medical technology company focused on improving health and simplifying life for people with diabetes by developing and commercializing innovative technologies.

  • GlobeNewswire

    Valeritas Announces Reverse Stock Split

    Valeritas Holdings, Inc. (VLRX), a medical technology company and maker of V-Go® Wearable Insulin Delivery device, a simple, all-in-one, wearable insulin delivery option for patients with diabetes, today announced that its Board of Directors has declared a 1-for-20 reverse stock split of the Company’s common stock, which will be effective for trading purposes upon the commencement of trading on May 20, 2019. At that time, each 20 shares of issued and outstanding common stock and equivalents will be converted into one share of common stock. Any fractional shares that would result from the reverse stock split will be settled in cash.

  • GlobeNewswire

    Valeritas Exhibits at Taking Control of Your Diabetes Conferences

    Valeritas Holdings, Inc. (VLRX), a medical technology company and maker of V-Go® Wearable Insulin Delivery device, a simple, all-in-one, wearable insulin delivery option for patients with diabetes, today announced that it is exhibiting at three Taking Control of Your Diabetes (TCOYD) conferences and health fairs. Valeritas is also exhibiting at TCOYD conferences on October 12, 2019, in San Diego, CA and November 2, 2019, in Charlotte, NC.

  • Valeritas Holdings, Inc. (VLRX) Reports Q1 Loss, Tops Revenue Estimates
    Zacks

    Valeritas Holdings, Inc. (VLRX) Reports Q1 Loss, Tops Revenue Estimates

    Valeritas Holdings, Inc. (VLRX) delivered earnings and revenue surprises of 0.00% and 3.27%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?